Acute hypercapnic
respiratory failure, COPD exacerbation, acute cardiogenic pulmonary edema, pre-oxygenation, do-not-intubate, weaning from mechanical ventilation
 |
NPPV, NIPPV, noninvasive ventilation (NIV), BiPAP/Bilevel, PSV, CPAP, respiratory failure, mask ventilation, and ventilator-associated complications reduction |
Clinical Assessment and Indications:
Thorough patient assessment is critical prior to the initiation of NPPV. Clinical trials and subsequent meta-analyses demonstrate that NPPV is beneficial in the management of:
Chronic obstructive pulmonary disease (COPD) exacerbations.
Cardiogenic pulmonary edema.
Immunocompromised patients with acute respiratory failure.
Patients with hypoxemic respiratory failure.
For starting NPPV for COPD exacerbations if the patient has no contraindications and meets two or more of the following: a) respiratory distress with moderate to severe dyspnea, arterial
pH < 7.35 with PaCO2 > 45, and a respiratory rate ≥ 25 breaths/min. In these patients, NPPV decreases intubation rates, mortality, complications, and length of hospital stay.
Contraindications for Noninvasive Positive Pressure Ventilation (NPPV) can be categorized into immediate life-threatening conditions, physiological instabilities, and physical barriers.
Contraindications
1.Noninvasive ventilation is strictly contraindicated in patients experiencing cardiac or respiratory arrest, as these situations require immediate invasive airway management. From a physiological standpoint.
2.NPPV should not be used if the patient is suffering from nonrespiratory organ failure, severe encephalopathy, or has a significantly impaired consciousness (typically defined as a Glasgow Coma Scale < 11).
3. Hemodynamic concerns, such as unstable cardiac rhythms or general hemodynamic instability, also preclude the use of NPPV due to the potential for further cardiovascular collapse under positive pressure.
3.Furthermore, several physical and safety factors serve as contraindications. These include a high risk for aspiration or severe upper gastrointestinal (UGI) bleeding, which could lead to airway contamination.
4.Patients must also be able to maintain their own airway; therefore, an inability to protect the airway, inability to clear secretions, or the presence of an upper airway obstruction are major deterrents.
5. Finally, anatomical issues such as facial surgery, trauma, or deformity often prevent the achievement of a proper mask seal, making the therapy ineffective
Indications for NPPV
COPD exacerbations
Cardiogenic pulmonary edema
Hypoxemic respiratory failure in immunocompromised hosts with pulmonary infiltrates
Weaning adjunct in COPD
Initiation of NPPV
Phase 1: Initial Screening
The process begins by evaluating a patient with a COPD exacerbation who meets at least two of the following: moderate to severe dyspnea,
pH < 7.35 with PaCO2 > 45, or a respiratory rate ≥25 breaths/min. Adjunctive therapies such as oxygen, bronchodilators, steroids, and antibiotics should be administered simultaneously.
Phase 2: Contraindication Check
The clinician must then assess for contraindications, including impending arrest, encephalopathy, active GI bleeding, hemodynamic instability, or facial trauma. If any contraindication is identified, the clinician should proceed immediately with intubation if clinically indicated.
Phase 3: Setup and Titration
If no contraindications exist, NPPV is initiated. The patient’s bed should be elevated, and the procedure explained. A properly sized full-face mask is selected and strapped loosely. Initial settings typically start with an Inspiratory Positive Airway Pressure (IPAP) of 12 and an Expiratory Positive Airway Pressure (EPAP) of 5. FiO2 is titrated to keep oxygen saturation > 90%. The IPAP should be increased in increments of 4cmH2O to reach a goal that reduces dyspnea and ensures adequate tidal volume, up to a maximum IPAP of 20-24 cm H2O.
Phase 4: Evaluation
The patient is reassessed for improvement (decreased respiratory rate, improved PaCO2/pH after 1 hour, and adequate synchrony with the ventilator). If the patient does not improve, intubation is required. If the patient improves, NPPV and adjunctive therapies are continued with frequent reassessment and determination of the appropriate hospital location for ongoing care.
Ventilator Settings and Interface
Physicians must select the mode, interface, and settings carefully. IPAP assists inspiration and lowers the level of inspiratory muscle work, while EPAP helps unload inspiratory muscles and recruit closed airways. Full facial masks are often preferred in acute settings because they minimize air leaks through the mouth, though they carry a higher risk of aspiration and skin necrosis if overtightened. Monitoring must be frequent, as NPPV failure is more likely in patients with a pH < 7.25 or a respiratory rate > 30 breaths/min.